News Quantified

CLLS – cellectis s.a. - american depositary shares (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca [Yahoo! Finance]

Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca

Cellectis S.A. (NASDAQ: CLLS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

Cellectis Appoints Arthur Stril as Interim Chief Financial Officer [Yahoo! Finance]

Cellectis Appoints Arthur Stril as Interim Chief Financial Officer

-13.1%

IN-LINE

-5.1%

BEAT

Form 6-K Cellectis S.A. For: May 06

Form 6-K Cellectis S.A. For: May 02

Form 20-F Cellectis S.A. For: Dec 31

Form 6-K Cellectis S.A. For: Apr 22

Form 6-K Cellectis S.A. For: Apr 10

Top News Gainers

12/17 3 “Strong Buy” Healthcare Stocks That Can Double in 2020 [Yahoo! Finance News] 14.3%

4/13 Cellectis Appoints Carrie Brownstein, M.D., as Chief Medical Officer 13.0%

2/18 Cellectis and Servier Expand Collaboration on UCART19 Products 9.2%

10/29 Form 6-K Cellectis S.A. For: Oct 29 7.5%

8/7 Cellectis: Monthly Information on Share Capital and Company Voting Rights 6.6%

1/9 Cellectis: Monthly Information on Share Capital and Company Voting Rights 5.7%

8/17 Cellectis SA (NASDAQ: CLLS) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 5.0%

10/31 Cellectis to Hold Third Quarter and First Nine Months 2019 Earnings Call on Thursday, November 7, 2019 at 8:00 AM EST 4.0%

11/8 Cellectis: Monthly information on share capital and company voting rights 3.8%

2/12 Cellectis SA (NASDAQ: CLLS) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 3.5%

Top News Decliners

3/6 Cellectis: Monthly Information on Share Capital and Company Voting Rights -17.3%

2/21 Cellectis SA (NASDAQ: CLLS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $22.00 price target on the stock. -9.5%

4/29 Cellectis to Hold First Quarter 2020 Earnings Call on Thursday, May 7, 2020 at 7:30 AM EDT -8.3%

4/15 Cellectis SA (NASDAQ: CLLS) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -8.0%

3/10 Form 6-K Cellectis S.A. For: Mar 10 -8.0%

10/1 Cellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis’ Allogeneic UCART Product Candidates -7.9%

3/5 Cellectis SA (CLLS) Q4 2019 Earnings Call Transcript [The Motley Fool] -7.0%

6/5 Cellectis: Monthly Information on Share Capital and Company Voting Rights -5.9%

4/23 Cellectis SA (NASDAQ: CLLS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -4.7%

4/2 Cellectis SA (NASDAQ: CLLS) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -4.6%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day